Juno Therapeutics, Inc.
Juno Therapeutics, Inc., a prominent player in the biopharmaceutical industry, is headquartered in the United States, with significant operations across various regions. Founded in 2013, the company has rapidly established itself as a leader in the development of innovative cell therapies, particularly in the field of oncology.
Juno is renowned for its pioneering work in CAR T-cell therapy, which harnesses the body’s immune system to target and eliminate cancer cells. This unique approach has led to groundbreaking treatments that have transformed patient outcomes in certain blood cancers.
With a strong market position, Juno Therapeutics has achieved notable milestones, including successful clinical trials and partnerships that enhance its research capabilities. The company continues to push the boundaries of cancer treatment, striving to deliver life-changing therapies to patients worldwide.
+38 vs industry average
Juno Therapeutics, Inc.’s score of 76 is higher than 86% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Juno Therapeutics, Inc.?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Reported emissions
No reported emissions data is available for Juno Therapeutics, Inc. yet.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Juno Therapeutics, Inc.’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Juno Therapeutics, Inc. yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives

Science Based Targets Initiative
Inherited from Bristol-Myers Squibb Company
Carbon Disclosure Project
Inherited from Bristol-Myers Squibb CompanyThe Climate Pledge
UN Global Compact Climate Champions initiative
Inherited from Bristol-Myers Squibb CompanyRE 100
Climate Action 100
Emissions comparison with industry peers
View similar organisationsUsage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project